A NEW PROMISING DRUG FOR ALZHEIMER’S — OPPORTUNITY FOR INVESTORS

Alzheimer’s

Alzheimer’s is a terrible disease.  A new patient is diagnosed with Alzheimer’s in the United States every 65 seconds.  More than 5.8 million Americans are living with Alzheimer’s.  For those who are over 65, one in 10 has Alzheimer’s dementia.

There is no cure.  Now a new treatment is on the horizon. If the treatment works, can you imagine the investment potential?

New Drug

FDA Advisory Committee panel sees ‘substantial evidence’ for approval of Alzheimer’s drug from Biogen (BIIB). BIIB is in the Arora Report Portfolio.

We previously wrote:

If the drug ultimately works and is approved, BIIB may ultimately exceed $2,000.

The stock is up over $100, trading around $350 as of this writing.

There are still a number of risks ahead.  It is also not known how well the drug works.  There are also likely to be several safety concerns that are not in the headlines at this time.

This is a high risk high reward situation suitable only for those who understand the risks and rewards of a biotech working on Alzheimer’s.

Zones

For those following the Good Way and are super aggressive, the Buy Now rating is ‘YES’ for a very, very small scale in.

For those following the Best Way, the buy zone is $281 to $331.56.

The mental stop zone is $200 to $213.

The quantity depends on your personal risk preference and the composition of the rest of your portfolio.   Most investors may consider a quantity of 5 – 25% of full core position size.

What To Do Now

Those in the stock may consider continuing to hold.

The not in the stock may consider following the parameters given above.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.   These trades have been scrutinized in real-time by thousands of investors across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on this trade but since the entry trade was not posted here for the free subscribers in real-time but only made available to the paying subscribers, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.

With the exception of the introduction, this post was published yesterday on ZYX Buy Change Alert.

 

A knowledgeable investor would have turned $100,000 into over $1,000,000 with the help from The Arora Report. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

A MAJOR WEALTH GENERATION OPPORTUNITY IS AHEAD IN ALZHEIMER’S DRUGS

For the first time in two decades, the FDA has approved a new Alzheimer's drug.  The drug is  from Biogen ...

A MENACING PATTERN HAS REVEALED ITSELF IN THE STOCK MARKET $FB $AAPL $AMZN $NVDA $AMD $TSLA $INTC $EXPE $XOM $AMGN $AMAT $WDC $EA

Prudent investors ought to pay attention to a menacing pattern developing in the stock market. Please click here for an annotated ...

ACORDA THERAPEUTICS (ACOR) AND BIOGEN (BIIB) RUMOR MONGERS OUT IN FORCE

Acorda Therapeutics (ACOR)  rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen ...

Follow

Get every new post delivered to your Inbox

Join other followers